Next Article in Journal
Therapeutic Management of Chronic Lymphocytic Leukemia Presenting with Recurrent Massive Ascites
Previous Article in Journal
Classification of Pediatric Gangliogliomas Based on the Histological Infiltration
Previous Article in Special Issue
Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma
 
 
Case Report

Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice

1
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy
2
Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy
3
Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCSS, 33081 Aviano, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(10), 6776-6786; https://doi.org/10.3390/curroncol29100533
Received: 25 July 2022 / Revised: 11 September 2022 / Accepted: 16 September 2022 / Published: 22 September 2022
(This article belongs to the Special Issue Beyond Immunotherapy in the Management of Genito-Urinary Malignancies)
The advent of immune checkpoint inhibitors in combination with multitarget tyrosine kinase inhibitors has become a standard first-line treatment for metastatic renal cell cancer. Along with survival improvement, new toxicities have emerged. Such adverse events are still complex to be managed and some of them are rare and could be insidious or even fatal. Medical oncologists dispose of guidelines about the management of toxicities from immune checkpoint inhibitors but not for combinations. Therefore, it is still difficult to properly attribute and manage additive or overlapping adverse events. We report two clinical cases regarding rare treatment-related endocrine toxicities—hypophysitis and thyroiditis—with particular focus on their management. To this purpose, immune checkpoint-related toxicities guidelines represent the starting point. However, their implementation with additional measures is needed, considering the increasing complexity of current clinical scenarios. The goal is to correctly recognize adverse events and address side effects, so as not to discontinue effective treatments. We, therefore, aim at discussing the points of proper management of toxicities and individuating potential areas of improvement. View Full-Text
Keywords: renal cell cancer; multidisciplinary team; immunotherapy; targeted therapy; toxicities renal cell cancer; multidisciplinary team; immunotherapy; targeted therapy; toxicities
Show Figures

Figure 1

MDPI and ACS Style

Dri, A.; Garattini, S.K.; Cinausero, M.; Macerelli, M.; Fanelli, M.; Puglisi, F.; Fasola, G.; Ermacora, P. Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice. Curr. Oncol. 2022, 29, 6776-6786. https://doi.org/10.3390/curroncol29100533

AMA Style

Dri A, Garattini SK, Cinausero M, Macerelli M, Fanelli M, Puglisi F, Fasola G, Ermacora P. Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice. Current Oncology. 2022; 29(10):6776-6786. https://doi.org/10.3390/curroncol29100533

Chicago/Turabian Style

Dri, Arianna, Silvio Ken Garattini, Marika Cinausero, Marianna Macerelli, Martina Fanelli, Fabio Puglisi, Gianpiero Fasola, and Paola Ermacora. 2022. "Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice" Current Oncology 29, no. 10: 6776-6786. https://doi.org/10.3390/curroncol29100533

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop